Median Technologies · EURONEXT:ALMDT
Median Technologies — Cowen & Co 43rd Health Care Conference 2023
26 slides from Median Technologies's conference presentation, Mar 7, 2023
Slide 1: Corporate Presentation
Corporate Presentation March 7, 2023 Cowen & Co 43rd Health Care Conference Boston | MA | USA Fredrik Brag CEO & Founder
Slide 2: Disclaimer
Disclaimer • The information provided in this presentation pertaining to Median Technologies SA . ("Median" or the "Company"), its business assets, strategy and operations is for general informational purposes only and is not a formal offer to sell or a solicitation of an offer to buy any securities
Slide 3: Early Diagnosis Saves Lives
Early Diagnosis Saves Lives Our strength is our people: 230+ highly qualified professionals in the US, Europe and China, 25+ nationalities. We are helping conquer cancer and Our growth is powered by proprietary AI, computer fibrotic diseases by extracting vision and signal processing technologies, s
Slide 4: AI-Powered Imaging and Data-Driven Approaches Are Redefining the Entire Patient Journey
AI-Powered Imaging and Data-Driven Approaches Are Redefining the Entire Patient Journey Generating more Adding more Providing more AI-driven data value to oncology accurate for oncology trials AI-driven diagnosis drug development • Extract drug efficacy data • Select early-stage patient • Develop no
Slide 5: Executive Committee
Executive Committee Fredrik Brag Jean-Christophe Yan Liu Thomas Nicolas Dano Montigny Bonnefont CEO & Founder Chief Financial Officer Chief Medical Officer Chief Operating & Chief Operating Officer Commercial Officer iCRO iBiopsy® 5 www.mediantechnologies.com | March 2023 | Cowen & Co Annual Health
Slide 6: Board of Directors
Board of Directors Bringing significant industry, medical, financial and strategic expertise to the company Oran Muduroglu Fredrik Brag Kapil Dhingra Oern Stuge Tim Haines Chairman Director Director Director Director 6 www.mediantechnologies.com | March 2023 | Cowen & Co Annual Health Care Conferenc
Slide 7: Strong Business Momentum
Strong Business Momentum As of December 31, 2022 (*) Revenue 2019-2022 (m€) 25 23.8 20.5 20 2022 revenue at €23.8M 15 13.5 • An increase of 16% compared to 10 9 2021 revenue (€20.5M). 5 Nota: company revenue comes from the iCRO activity, as iBiopsy® doesn’t generate revenue at this stage (R&D) 0 Ful
Slide 8: 2023 & Beyond: Transformative Developments
2023 & Beyond: Transformative Developments Growing penetration of AI imaging Growing penetration of AI imaging in patient care in the pharma industry ▪ Lung cancer is the N°1 killer of all cancers with 94% mortality at ▪ Median core iCRO business is expected to grow significantly 5 years for late st
Slide 9: iBiopsy®
iBiopsy® Shifting the Early Diagnostic Paradigm with Artificial Intelligence We are developing the next generation AI/ML tech-based Software as Medical Device (SaMD) to help: • Detect, diagnose & monitor early-stage lung and liver cancer patients • Detect, diagnose & monitor early-stage NAFLD/NASH p
Slide 10: iBiopsy® Platform
iBiopsy® Platform iBiopsy® leverages Median’s expertise and capabilities to design the most advanced AI/ML tech-based CADe/CADx SaMD Medical device & • Create the next generation of Pharma Landscapes AI/ML CADe/CADx SaMD Scientific and Technology portfolio expertise in signal/image • Achieve unprece
Slide 11: iBiopsy® Recent Landmark Events
iBiopsy® Recent Landmark Events We published breakthrough We prepared our pivotal clinical results & obtained endorsement We prepared the next steps studies from the medical community • Publications of significant • Design of the LCS pivotal clinical • Design of LCS SaMD market scientific and clinic
Slide 12: iBiopsy® Integration in the Radiology Workflow
iBiopsy® Integration in the Radiology Workflow Pa ent is scanned mage is stored in P o user interac on, full automa on mage is transferred to the iBiopsy D M report is iBiopsy processing generated and sent to the through iBiopsy ateway P through the iBiopsy ateway 12 www.mediantechnologies.com | Mar
Slide 13: iBiopsy® Total Addressable Market
iBiopsy® Total Addressable Market High opportunity across all indications Lung Cancer Incidental Pulmonary HCC Detection and NAFLD/NASH Screening Nodules Diagnosis Detection and Diagnosis Total Addressable ~$10-20bn ~$5-10bn ~$1-3bn ~$16-50bn Market Market Facts N°1 Killer with 5% 10M people in the
Slide 14: AI-based Software as Medical Device Landscape in the US
AI-based Software as Medical Device Landscape in the US • The recognition of AI-SaMD value has translated: • in specific temporally NTAP (new Technology Add-on Payment) reimbursement codes, • in a growing number of AI imaging CPT (Current Procedural Terminology ) III codes. • These CPT codes allow a
Slide 15: iBiopsy® LCS: Setting the Bar in Lung Cancer Screening
iBiopsy® LCS: Setting the Bar in Lung Cancer Screening Lung nodule detection & characterization on all lung cancer stages Receiver Operating Characteristic Test • Nodule Level Performance – AUC = 0.974 – Max Youden Index Operating Point : Sensitivity = 96.5 % Specificity = 97.2 % • Dataset – Trainin
Slide 16: Clinical Validation Plan: A Two Study Approach
Clinical Validation Plan: A Two Study Approach Objective: Meet the regulatory requirements (USA, EU, etc) for End-to-End CADe/CADx Standalone Performance Study Multi-Reader Multi-Case Study • 4-6 Centers, ≥294 cancer, ≥521 benign • 360 total patients, 4-6 centers: 120 cancer, 240 benign • Objectives
Slide 17: iBiopsy® Lung & Liver SaMD suites roadmap
iBiopsy® Lung & Liver SaMD suites roadmap 2021 2022 2023 2024 2025 1ST Half 2nd Half 1ST Half 2nd Half 1ST Half 2nd Half 1ST Half 2nd Half 1ST Half 2nd Half CADe/CADx Development FDA Lung Cancer Pivotal study protocol definition Pivotal study execution Approval CE Mark Screening (LCS) Interactions w
Slide 18: iBiopsy®: Strategy and Key Plans for 2023
iBiopsy®: Strategy and Key Plans for 2023 1. 2. 3. LCS SaMD pivotal LCS SaMD 510(K) LCS SaMD Go to clinical studies filing with FDA Market plans Reimbursement & HE studies 4. 5. 6. Continue to develop Develop a strategic Continued progress strategic relation- partnership with a on IPN, HCC & NASH sh
Slide 19: iCRO
iCRO Adding more values to oncology clinical trials and drug development programs We provide our global biopharma customers: • With key data on patient response from phases I to phases III, • With Imaging Lab services, driving drug development success with transformative AI insights. 19 www.mediante
Slide 20: iCRO Landscape and Differentiators
iCRO Landscape and Differentiators Landscape One TA-focused • The imaging CRO market size was valued at imaging CRO USD 1.5bn in 2021. The largest market Neurology Oncology segment is for oncology. & CNS • On April 28, 2021, ERT and Bioclinica closed their merger in a $7.8bn deal -> Clario Regional
Slide 21: Imaging CRO Solutions and Services
Imaging CRO Solutions and Services Bringing more meaning to image data: iSee® 21 www.mediantechnologies.com | March 2023 | Cowen & Co Annual Health Care Conference
Slide 22: iCRO Global Experience and Oncology Expertise
iCRO Global Experience and Oncology Expertise As of December 31, 2022 Clients in the US 55 and Europe 20+ Clients in China, including the Top3 Chinese Biopharmas 220 Oncology Studies 32 109 79 17 Supported Regulatory 26,000+ Phase I Phase II Phase III Approvals trials trials trials Enrolled Patients
Slide 23: Imaging Lab: Median's added value in the Life Cycle of Drug Development
maging Lab: Median’s added value in the Life ycle of Drug Development Image Intelligence all along the Patient Journey & Drug Development Process 23 www.mediantechnologies.com | March 2023 | Cowen & Co Annual Health Care Conference
Slide 24: iCRO: Strategy and Key Plans for 2023
iCRO: Strategy and Key Plans for 2023 1. 2. 3. Continue to scale & Become preferred Strike major Imaging grow the core partner with Lab deals with Top business additional large Pharma Companies, pharmas based on an Artificial Intelligence offer 24 www.mediantechnologies.com | March 2023 | Cowen & Co
Slide 25: Wrap Up messages - 2023 & 2024: Transformative developments
Wrap Up messages - 2023 & 2024: Transformative developments iBiopsy® Lung Cancer Screening AI-based CADe/CADx SaMD: • iBiopsy®LCS CADe/CADx pivotal study execution in 2023 • iBiopsy® LCS CADe/CADx expected FDA approval H1 2024 AI is very rapidly becoming a Must Have in drug development: • Median to
Slide 26: Our Core Values
Our Core Values Leading innovation with purpose Combine the spirit of innovation with our passion and conviction to help cure cancer and other debilitating diseases. Committing to quality in all we do Be dedicated to quality in everything we do. Quality begins with us and we are committed to it. Sup
Median Technologies — Cowen & Co 43rd Health Care Conference 2023 on 6ix